Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7568282 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| RO7568282 High Dose | EXPERIMENTAL | Participants will receive high dose of RO7568282. |
| RO7568282 Low Dose | EXPERIMENTAL | Participants will receive low dose of RO7568282. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive RO7568282 matching placebo. |
| Name | Type | Description |
|---|---|---|
| RO7568282 | DRUG | RO7568282 will be administered as specified in the protocol. |
| Placebo | DRUG | RO7568282 matching placebo will be administered as specified in the protocol. |
Inclusion Criteria: * Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF) * Mild cognitive impairment (MCI) or mild dementia due to AD * Able to swallow whole capsules * Body mass index (BMI) within the range of 18...
Top 20 of 24 competitors
RO7568282 is an investigational small molecule being developed by Roche Holding AG (RHHBY) for the treatment of Parkinson's Disease and Alzheimer's Disease. It is currently in Phase 2 clinical development for these neurological conditions.
RO7568282 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's effects and safety in patients with early Parkinson's Disease and early symptomatic Alzheimer's Disease.
RO7568282 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Roche is currently conducting trials to assess its safety and efficacy in Parkinson's Disease and Alzheimer's Disease.
RO7568282 is being studied in two clinical trials: NCT07781644, a Phase 1 study in early Parkinson's Disease with 474 participants, and NCT07781657, a Phase 2 study in early symptomatic Alzheimer's Disease with 450 participants. Both trials are not yet recruiting and are placebo-controlled, randomized, and double-blind.
No alternative names for RO7568282 have been disclosed. It is identified solely by its compound code RO7568282 in clinical trial registrations and by Roche Holding AG.